Efficient inhibition of ovarian cancer by short hairpin RNA targeting claudin-3

Oncology Reports

Volumn 26, Issue 1, 2011, Pages 193-200

  Sun, Chuntang ^a   Yi, Tao ^a   Song, Xiangrong ^b   Li, Shuangzhi ^b   Qi, Xiaorong ^a   Chen, Xiancheng ^b   Lin, Honggang ^b   He, Xiang ^a   Li, Zhengyu ^a   Wei, Yuquan ^b   Zhao, Xia ^a  

^a SICHUAN UNIVERSITY   (China)

^b SICHUAN UNIVERSITY   (China)

Author keywords

CLD N3; Nanoparticles; Ovarian cancer; PLGA; RNA interference; shRNA

Indexed keywords

CD31 ANTIGEN; CLAUDIN 3; KI 67 ANTIGEN; NANOPARTICLE; POLYGLACTIN; SHORT HAIRPIN RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL DENSITY; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFICACY; ENCAPSULATION; FEMALE; GENE DELIVERY SYSTEM; GENE TARGETING; GROWTH INHIBITION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NICK END LABELING; NONHUMAN; OVARY CANCER; PLASMID; PRIORITY JOURNAL; TUMOR VOLUME; ZETA POTENTIAL;

ANTIGENS, CD31; APOPTOSIS; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; FEMALE; GENETIC VECTORS; HUMANS; IN SITU NICK-END LABELING; KI-67 ANTIGEN; MEMBRANE PROTEINS; MICROCIRCULATION; OVARIAN NEOPLASMS; RNA, SMALL INTERFERING; TRANSFECTION;

EID: 79955810492     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2011.1275     Document Type: Article

References (43)

1. Jemal A, Siegel R, Xu J and Ward E: Cancer statistics, 2010. CA Cancer J Clin 60: 277-300, 2010.
2. DiSaia PJ and Creasman WT: Epithelial ovarian cancer. In: Clinical Gynecologic Oncology. 5th edition. DiSaia PJ and Creasman WT (eds). Mosby, St. Louis, 1997.
3. Jemal A, Siegel R, Ward E, Hao Y, Xu J and Thun MJ: Cancer statistics, 2009. CA Cancer J Clin 59: 225-249, 2009.
4. Clark PR and Hersh EM: Cationic lipid-mediated gene transfer: current concepts. Curr Opin Mol Ther 1: 158-176, 1999. (Pubitemid 29238421)
5. Cristiano RJ: Viral and non-viral vectors for cancer gene therapy. Anticancer Res 18: 3241-3245, 1998.
6. Merdan T, Kopecek J and Kissel T: Prospects for cationic polymers in gene and oligonucleotide therapy against cancer. Adv Drug Deliv Rev 54: 715-758, 2002. (Pubitemid 35247524)
7. Jabbarzadeh E, Starnes T, Khan YM, et al: Induction of angiogenesis in tissue-engineered scaffolds designed for bone repair: a combined gene therapy-cell transplantation approach. Proc Natl Acad Sci USA 105: 11099-11104, 2008.
8. Hao T, McKeever U and Hedley ML: Biological potency of microsphere encapsulated plasmid DNA. J Control Release 69: 249-259, 2000.
9. Panyam J, Zhou WZ, Prabha S, Sahoo SK and Labhasetwar V: Rapid endo-lysosomal escape of poly(DL-lactide-co-glycolide) nanoparticles: implications for drug and gene delivery. FASEB J 16: 1217-1226, 2002. (Pubitemid 34815409)
10. Li Z and Huang L: Sustained delivery and expression of plasmid DNA based on biodegradable polyester, poly(D,L-lactide-co-4-hydroxy-L-proline). J Control Release 98: 437-446, 2004 (Pubitemid 39093954)
11. Song X, Zhao Y, Wu W, et al: PLGA nanoparticles simultaneously loaded with vincristine sulfate and verapamil hydrochloride: systematic study of particle size and drug entrapment efficiency. Int J Pharm 350: 320-329, 2008. (Pubitemid 351146679)
12. Song XR, Cai Z, Zheng Y, et al: Reversion of multidrug resistance by co-encapsulation of vincristine and verapamil in PLGA nanoparticles. Eur J Pharm Sci 37: 300-305, 2009.
13. Morita K, Furuse M, Fujimoto K and Tsukita S: Claudin multigene family encoding four-transmembrane domain protein components of tight junction Strands. Proc Natl Acad Sci USA 96: 511-516, 1999. (Pubitemid 29061239)
14. Hough CD, Sherman-Baust CA, Pizer ES, et al: Large-scale serial analysis of gene expression reveals genes differentially expressed in ovarian cancer. Cancer Res 60: 6281-6287, 2000.
15. Rangel LB, Agarwal R, D'Souza T, et al: Tight junction proteins claudin-3 and claudin-4 are frequently overexpressed in ovarian cancer but not in ovarian cystadenomas. Clin Cancer Res 9: 2567-2575, 2003. (Pubitemid 36842098)
16. Agarwal R, D'Souza T and Morin PJ: Claudin-3 and claudin-4 expression in ovarian epithelial cells enhances invasion and is associated with increased matrix metalloproteinase-2 activity. Cancer Res 65: 7378-7385, 2005. (Pubitemid 41161271)
17. Romani C, Comper F, Bandiera E, et al: Development and characterization of a human single-chain antibody fragment against claudin-3: a novel therapeutic target in ovarian and uterine carcinomas. Am J Obstet Gynecol 201: 70.e71-79, 2009.
18. Santin AD, Cane S, Bellone S, et al: Treatment of chemotherapy-resistant human ovarian cancer xenografts in C.BT7/SCID mice by intraperitoneal administration of Clostridium perfringens enterotoxin Cancer Res 65: 4334-4342, 2005.
19. Huang YH, Bao Y, Peng W, et al: Qaudin-3 gene silencing with siRNA suppresses ovarian tumor growth and metastasis. Proc Natl Acad Sci USA 106: 3426-3430, 2009.
20. Freytag T, Dashevsky A, Tillman L, Hardee GE and Bodmeier R: Improvement of the encapsulation efficiency of oligonucleotide-containing biodegradable microspheres. J Control Release 69: 197-207, 2000.
21. Cui FY, Song XR, Li ZY, et al: The pigment epithelial-derived factor gene loaded in PLGA nanoparticles for therapy of colon carcinoma. Oncol Rep 24: 661-668, 2010.
22. Song X, Zhao Y, Hou S, et al: Dual agents loaded PLGA nano-particles: systematic study of particle size and drug entrapment efficiency. Eur J Pharm Biopharm 69: 445-453, 2008.
23. Lin XJ, Chen XC, Wang L, et al: Dynamic progression of an intraperitoneal xenograft model of human ovarian cancer and its potential for preclinical trials. J Exp Qin Cancer Res 26: 467-474, 2007. (Pubitemid 351157862)
24. Mukherjee P, Abate LE and Seyfried TN: Antiangiogenic and proapoptotic effects of dietary restriction on experimental mouse and human brain tumors. Clin Cancer Res 10: 5622-5629, 2004. (Pubitemid 39100504)
25. Cohen H, Levy RJ, Gao J, et al: Sustained delivery and expression of DNA encapsulated in polymeric nanoparticles. Gene Ther 7: 1896-1905, 2000.
26. Ando S, Putnam D, Pack DW and Langer R: PLGA microspheres containing plasmid DNA: preservation of supercoiled DNA via cryopreparation and carbohydrate stabilization. J Pharm Sci 88: 126-130, 1999. (Pubitemid 29037379)
27. Folkman J: Tumor angiogenesis: therapeutic implications. N Engl J Med 285: 1182-1186, 1971.
28. Li CY, Shan S, Huang Q, et al: Initial stages of tumor cell-induced angiogenesis: evaluation via skin window chambers in rodent models. J Natl Cancer Inst 92: 143-147, 2000. (Pubitemid 30089871)
29. Folkman J: Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov 6: 273-286, 2007.
30. Isner JM and Asahara T: Angiogenesis and vasculogenesis as therapeutic strategies for postnatal neovascularization. J Clin Invest 103: 1231-1236, 1999. (Pubitemid 29218292)
31. Paddison PJ, Caudy AA, Bernstein E, Hannon GJ and Conklin DS: Short hairpin RNAs (shRNAs) induce sequence-specific silencing in mammalian cells. Genes Dev 16: 948-958, 2002. (Pubitemid 34408544)
32. Wannenes F, Ciafre SA, Niola F, Frajese G and Farace MG: Vector-based RNA interference against vascular endothelial growth factor-A significantly limits vascularization and growth of prostate cancer in vivo. Cancer Gene Ther 12: 926-934, 2005. (Pubitemid 41622259)
33. Zhang Y, Zhang YF, Bryant J, Charles A, Boado RJ and Pardridge WM: Intravenous RNA interference gene therapy targeting the human epidermal growth factor receptor prolongs survival in intracranial brain cancer. Clin Cancer Res 10: 3667-3677, 2004. (Pubitemid 38697600)
34. He Q, Liu J, Sun X and Zhang ZR: Preparation and characteristics of DNA-nanoparticles targeting to hepatocarcinoma cells. World J Gastroenterol 10: 660-663, 2004. (Pubitemid 38351531)
35. Morin PJ: Claudin proteins in human cancer: promising new targets for diagnosis and therapy. Cancer Res 65: 9603-9606, 2005.
36. Katahira J, Sugiyama H, Inoue N, Horiguchi Y, Matsuda M and Sugimoto N: Clostridium perfringens enterotoxin utilizes two structurally related membrane proteins as functional receptors in vivo. J Biol Chem 272: 26652-26658, 1997. (Pubitemid 27458889)
37. Kiuchi-Saishin Y, Gotoh S, Furuse M, Takasuga A, Tano Y and Tsukita S: Differential expression patterns of claudins, tight junction membrane proteins, in mouse nephron segments. J Am Soc Nephrol 13: 875-886, 2002. (Pubitemid 34274083)
38. Zelphati O, Uyechi LS, Barron LG and Szoka FC Jr: Effect of serum components on the physico-chemical properties of cationic lipid/oligonucleotide complexes and on their interactions with cells. Biochim Biophys Acta 1390: 119-133, 1998. (Pubitemid 28122331)
39. Diez S and Tros de Ilarduya C: Versatility of biodegradable poly(D,L-lactic-co-glycolic acid) microspheres for plasmid DNA delivery. Eur J Pharm Biopharm 63: 188-197, 2006. (Pubitemid 43776215)
40. Pan H, Jiang H and Chen W: The biodegradability of electrospun Dextran/PLGA scaffold in a fibroblast/macrophage co-culture. Biomaterials 29: 1583-1592, 2008.
41. Panyam J and Labhasetwar V: Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv Drug Deliv Rev 55: 329-347, 2003. (Pubitemid 36297053)
42. Jain RK: Transport of molecules in the tumor interstitium: a review. Cancer Res 47: 3039-3051, 1987.
43. Howell SB: Selection of drugs for intraperitoneal chemotherapy for ovarian cancer. In: Intraperitoneal Therapy for Ovarian Cancer. Alberts DS, Clouser MC and Hess LM (eds). Springer-Verlag, Heidelberg, pp77-88, 2010.